EPO Part B Claims Reimbursement To Follow Labeling On Dose Reduction
Executive Summary
The Centers for Medicare & Medicaid Services' final policy on Part B reimbursement for Amgen's Aranesp (darbepoetin alfa) and Epogen (epoeitin alfa) in end-stage renal disease follows product labeling recommendations that dosing be reduced when hematocrit levels reach a certain threshold